Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Up 90.8% in October

Aprea Therapeutics, Inc. (NASDAQ:APRE) saw a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 29,000 shares, a growth of 90.8% from the October 15th total of 15,200 shares. Currently, 0.6% of the company’s shares are short sold. Based on an average trading volume of 21,900 shares, the days-to-cover ratio is presently 1.3 days.

Analyst Ratings Changes

A number of brokerages recently commented on APRE. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Aprea Therapeutics in a report on Thursday, October 24th. Wedbush restated an “outperform” rating and issued a $11.00 price objective on shares of Aprea Therapeutics in a report on Tuesday, August 13th.

Insider Buying and Selling

In other news, Director Bernd R. Seizinger bought 10,000 shares of the company’s stock in a transaction dated Friday, October 11th. The stock was bought at an average cost of $2.68 per share, for a total transaction of $26,800.00. Following the completion of the acquisition, the director now owns 44,730 shares in the company, valued at approximately $119,876.40. This trade represents a 28.79 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Marc Duey sold 6,462 shares of the business’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $4.58, for a total value of $29,595.96. Following the transaction, the director now owns 233,651 shares in the company, valued at approximately $1,070,121.58. This represents a 2.69 % decrease in their position. The disclosure for this sale can be found here. Insiders have purchased a total of 42,290 shares of company stock worth $165,096 in the last ninety days. 12.80% of the stock is owned by insiders.

Institutional Trading of Aprea Therapeutics

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Stonepine Capital Management LLC acquired a new stake in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 137,174 shares of the company’s stock, valued at approximately $558,000. Aprea Therapeutics comprises about 0.5% of Stonepine Capital Management LLC’s holdings, making the stock its 21st largest holding. Stonepine Capital Management LLC owned approximately 2.53% of Aprea Therapeutics at the end of the most recent reporting period. 34.19% of the stock is owned by institutional investors.

Aprea Therapeutics Stock Performance

Shares of NASDAQ APRE traded down $0.10 during mid-day trading on Friday, hitting $3.25. 15,517 shares of the stock traded hands, compared to its average volume of 20,347. The company has a market cap of $17.65 million, a price-to-earnings ratio of -1.26 and a beta of 0.97. The stock has a fifty day moving average price of $3.34 and a 200-day moving average price of $3.92. Aprea Therapeutics has a 52 week low of $2.15 and a 52 week high of $8.85.

Aprea Therapeutics (NASDAQ:APRE) last released its earnings results on Thursday, November 7th. The company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.11. Aprea Therapeutics had a negative net margin of 1,029.50% and a negative return on equity of 57.86%. The firm had revenue of $0.35 million for the quarter, compared to the consensus estimate of $0.45 million. As a group, sell-side analysts predict that Aprea Therapeutics will post -2.56 EPS for the current fiscal year.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.